News
News Center
2023-11-04
On November 1, 2023, the kickoff meeting for the clinical trial of human bone marrow mesenchymal stem cell injection therapy for a rare lung disease—autoimmune alveolar proteinosis (aPAP)—co-sponsored by Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereafter referred to as "Jiuzhitang Maker") and the First Affiliated Hospital of Guangzhou Medical University (hereafter referred to as "Guangyi Yiyuan"), was successfully held. Academician Zhong Nanshan attended the entire event and provided guidance throughout the trial.
+
2023-10-10
Stem Cell Science Comic (8) | Stem Cells in the Treatment of Ischemic Stroke
Original science popularization article on stem cells!
+
2023-09-19
Stem Cell Science Comic (7) | Stem Cells for Treating Skin Photoaging
Original science popularization article on stem cells!
+
2023-08-15
Stem Cell Science Comic (6) | Stem Cells in COVID-19 Treatment
Original science popularization article on stem cells!
+![[Science and Technology Daily] Stem cell research could spark a revolution in medical technology](https://omo-oss-image.thefastimg.com/portal-saas/pg2024091209142318355/cms/image/ca716faf-6406-4d84-a280-c55d825e77a3.png "[Science and Technology Daily] Stem cell research could spark a revolution in medical technology")
2023-08-07
[Science and Technology Daily] Stem cell research could spark a revolution in medical technology
In recent years, rapidly advancing technologies such as spatial omics, single-cell spatiotemporal genomics sequencing, single-molecule techniques, ultra-sensitive proteomics analysis, and proximity labeling approaches have significantly propelled stem cell research, providing the technological foundation needed to achieve functional organ reconstruction.
+
2023-07-26
The main content of this guideline is divided into four sections: an overview, key considerations for communication, important notes, and examples. This guideline applies to communication regarding cell and gene therapy products based on clinical trial protocols.
+
2023-07-20
Recently, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereafter referred to as "Jiuzhitang Maker") received inspection reports from the China Institute of Food and Drug Control (hereafter referred to as "CIFDC"), confirming that human bone marrow mesenchymal stem cell products sourced from different donors and produced in various batches all met the required quality standards.
+
2023-07-20
Recently, according to the relevant provisions of the "Management Measures for the Construction and Operation of Key Laboratories in Hunan Province" (Hunan Science and Technology Development [2022] No. 173), 22 key laboratories in Hunan Province have been officially announced following procedures including organizational recommendations, expert consultations, and committee reviews. Among them is the "Hunan Provincial Key Laboratory for Critical Quality Attributes of Cell Therapy Products," which Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.—the stem-cell pharmaceutical enterprise under Jiuzhitang—has helped establish.
+
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy